All News
RheumNow Podcast – Take it Back Jack! (4.26.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleUstekinumab Effective in Behcet's Disease
A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).
Read ArticleHigher Comorbidities in Hidradenitis Suppurativa
JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.
Read ArticleMortality Risk Factors in Systemic Sclerosis
A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.
Read ArticleRheumNow Podcast – Loretta Lynn Arthritis (3.29.19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read ArticleAutoimmune Disease Clustering at ENDO 2019
A twin registry database study was presented at the Endocrine Society's annual meeting (ENDO 2019) in New Orleans, showed that that having autoimmune disease significantly increases the risk of other autoimmune disorders and that autoimmune clustering was highest in Addison's disease and vit
Read ArticleCyclosporin and IVIG Effective in Kawasaki's Disease
A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.
Read ArticleNo Rise in Cancer Risk with Actemra
In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.
Read ArticleBrazilian Guidelines for Systemic Autoimmune Myopathies
The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).
Read ArticleFirst Line IL-1 Inhibition in Systemic JIA
First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.
Read ArticleRheumNow Podcast – Scleroderma and the Lung (3.1.19)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read ArticleRheumNow Podcast - Death and Surgery (2-22-19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com:
Read ArticleImpressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study.
Read ArticleStopping Biologics Before Joint Surgery: Is Earlier Better?
Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.
Read ArticleMortality and Hospitalization with Pulmonary Hypertension in Systemic Sclerosis
PHAROS is a prospective cohort studying the natural history of pulmonary hypertension (PH) in systemic sclerosis (SSc). They have shown that risk factors for poor outcomes in this cohort included male sex, DLCO < 50%, exercise oxygen desaturation, and pericardial effusions.
Read ArticleNoninfectious Proximal Aortitis Needs Serial Follow-ups
A Cleveland Clinic review of patients undergoing thoracic aortic surgery (1996‐2012) identified 196 patients with histopathology‐proven non‐infectious aortitis.
Read ArticleRheumNow Podcast - Scurvy and Mechanics (2-1-19)
Dr. Jack Cush reviews new journal articles, news reports, and more from the past week on RheumNow.com.
Read ArticleMajor Challenges for Lupus in 2019
Despite striking improvements in survival among patients with systemic lupus erythematosus (SLE) in recent decades -- from 1-year survival of less than 50% before the introduction of prednisone to 90% today in most specialized treatment centers -- many challenges remain in this perplexing, multis
Read ArticleDoes Methotrexate Work in Giant Cell Arteritis?
There seems to be both hope and uncertainty regarding the use of weekly methotrexate (MTX) in giant cell arteritis (GCA) patients whom need to limit their glucocorticoid use.
Read ArticleIL-6 Blocker Succeeds in Real-World Vasculitis
Tocilizumab (Actemra) was effective for refractory giant cell arteritis (GCA) in real-world practice, although serious infections occurred relatively frequently, Spanish investigators reported.
Read Article


